TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
1 Year Est. Return
+125.1%
AUM
$1.97B
AUM Growth
-$55.4M
(-2.7%)
Holding
79
Top Buys
| 1 | +$93.8M | |
| 2 | +$50.2M | |
| 3 | +$45.3M | |
| 4 |
Insmed
INSM
|
+$30.7M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$26.9M |
Top Sells
| 1 | +$64.9M | |
| 2 | +$36.3M | |
| 3 | +$27.7M | |
| 4 |
Travere Therapeutics
TVTX
|
+$26.7M |
| 5 |
VTYX
Ventyx Biosciences
VTYX
|
+$25.4M |
Sector Composition
| 1 | Healthcare | 94.45% |
| 2 | Communication Services | 0% |
| 3 | Real Estate | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viking Therapeutics
VKTX
$3.46B
| $16.3M | 0.83% |
500,000
|
|
||
27
IDEAYA Biosciences
IDYA
$2.57B
| $15M | 0.76% |
450,000
|
|
||
28
Nuvation Bio
NUVB
$1.8B
| $13.5M | 0.69% |
3,149,557
-707,900
|
|
||
29
Pliant Therapeutics
PLRX
$72.4M
| $7.74M | 0.39% |
6,143,132
|
|
||
30
Journey Medical
DERM
$171M
| $7.55M | 0.38% |
1,610,000
-244,596
|
|
||
31
Janux Therapeutics
JANX
$839M
| $6.95M | 0.35% |
+500,000
|
|
||
32
Biogen
BIIB
$29B
| $6.42M | 0.33% |
35,000
|
|
||
33
UroGen Pharma
URGN
$1.34B
| $6.29M | 0.32% |
350,000
|
|
||
34
Arvinas
ARVN
$499M
| $5.71M | 0.29% |
538,658
-31,040
|
|
||
35
PMV Pharmaceuticals
PMVP
$63.5M
| $5.26M | 0.27% |
4,245,085
-694,915
|
|
||
36
Moderna
MRNA
$20.5B
| $5.08M | 0.26% |
100,000
-592,820
|
|
||
37
Heron Therapeutics
HRTX
$91.5M
| $5M | 0.25% |
6,250,000
|
|
||
|
KZR
38
DELISTED
Kezar Life Sciences
KZR
| $4.93M | 0.25% |
664,314
|
|
||
39
Wave Life Sciences
WVE
$1.17B
| $4.35M | 0.22% |
600,000
|
|
||
|
LENZ
40
LENZ Therapeutics
LENZ
$226M
| $4.13M | 0.21% |
451,114
-414,055
|
|
||
41
Agios Pharmaceuticals
AGIO
$1.71B
| $3.38M | 0.17% |
+100,000
|
|
||
42
Erasca
ERAS
$4.13B
| $3.24M | 0.16% |
200,000
-700,000
|
|
||
43
Coherus Oncology
CHRS
$242M
| $3.19M | 0.16% |
1,886,748
-837,761
|
|
||
44
Nkarta
NKTX
$198M
| $3.12M | 0.16% |
1,480,823
|
|
||
45
Altimmune
ALT
$568M
| $2.05M | 0.1% |
666,022
-1,465,285
|
|
||
46
Evolus
EOLS
$435M
| $1.99M | 0.1% |
483,021
-762,671
|
|
||
47
Abeona Therapeutics
ABEO
$332M
| $1.79M | 0.09% |
400,000
-600,000
|
|
||
48
Fate Therapeutics
FATE
$258M
| $1.4M | 0.07% |
1,167,773
|
|
||
49
Neumora Therapeutics
NMRA
$324M
| $858K | 0.04% |
439,878
-527,357
|
|
||
50
Lexicon Pharmaceuticals
LXRX
$844M
| $624K | 0.03% |
+399,700
|
|